ISIS Pharmaceuticals, Inc. Share Price Nasdaq
Equities
US4643301090
Biotechnology & Medical Research
Sales 2024 * | 597M 47B | Sales 2025 * | 767M 60.34B | Capitalization | 5.65B 445B |
---|---|---|---|---|---|
Net income 2024 * | -577M -45.42B | Net income 2025 * | -519M -40.85B | EV / Sales 2024 * | 8.51 x |
Net cash position 2024 * | 567M 44.63B | Net Debt 2025 * | 318M 25.03B | EV / Sales 2025 * | 7.78 x |
P/E ratio 2024 * |
-10.1
x | P/E ratio 2025 * |
-11.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.13% |
Latest transcript on ISIS Pharmaceuticals, Inc.
Managers | Title | Age | Since |
---|---|---|---|
D. Walke
FOU | Founder | 58 | 30/06/12 |
Brett Monia
FOU | Founder | 62 | 09/01/89 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 62 | 30/04/00 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Loscalzo
CHM | Chairman | 72 | 02/02/14 |
Brett Monia
FOU | Founder | 62 | 09/01/89 |
Joan Herman
BRD | Director/Board Member | 70 | 09/06/19 |
1st Jan change | Capi. | |
---|---|---|
+41.97% | 54.04B | |
+43.57% | 41.96B | |
-1.16% | 41.92B | |
-7.59% | 28.35B | |
+12.16% | 26.35B | |
-22.69% | 19B | |
+7.81% | 13B | |
+28.70% | 12.28B | |
+25.41% | 12.19B |